Skip to main content

Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications

Edited by: 
Chung-Tsen Hsueh:
Loma Linda University, USA
Delong Liu: New York Medical College, USA

Submission Status: Closed   |   Submission Deadline: Closed

This collection is no longer accepting submissions


Biomarker Research is calling for submissions to our Collection on "Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications." 

This series intends to collect studies on latest developments in new technologies and clinical applications on liquid biopsy, cfDNA, and ctDNA. Discovery and validation of new biomarkers for diagnosis, therapy and prognosis for human diseases are welcome too.

Articles published in the collection have already gone through the systematic peer review process of the journal.

About the collection

Biomarker Research is calling for submissions to our Collection on "Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications."

This series intends to collect studies on latest developments in new technologies and clinical applications on liquid biopsy, cfDNA, and ctDNA. Discovery and validation of new biomarkers for diagnosis, therapy and prognosis for human diseases are welcome too.

Image credit: © [M] Connect world / stock.adobe.com

  1. Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising approach for cancer therapy with an expectation of no significant side effects. In the human body, mature T cells are armed...

    Authors: Zhi Pang, Man-man Lu, Yu Zhang, Yuan Gao, Jin-jin Bai, Jian-ying Gu, Lu Xie and Wei-zhong Wu
    Citation: Biomarker Research 2023 11:104
  2. Today, adoptive cell therapy has many successes in cancer therapy, and this subject is brilliant in using chimeric antigen receptor T cells. The CAR T cell therapy, with its FDA-approved drugs, could treat sev...

    Authors: Kaveh Hadiloo, Siavash Taremi, Mahmood Heidari and Abdolreza Esmaeilzadeh
    Citation: Biomarker Research 2023 11:103
  3. Tumor-associated macrophages (TAMs), one of the most abundant immune cell types in the tumor microenvironment (TME), account for approximately 50% of the local hematopoietic cells. TAMs play an important role ...

    Authors: Manli Zhou, Xiaoyun He, Cheng Mei and Chunlin Ou
    Citation: Biomarker Research 2023 11:100
  4. While the field of precision oncology is rapidly expanding and more targeted options are revolutionizing cancer treatment paradigms, therapeutic resistance particularly to immunotherapy remains a pressing chal...

    Authors: Karama Asleh, Valerie Dery, Catherine Taylor, Michelle Davey, Marie-Ange Djeungoue-Petga and Rodney J. Ouellette
    Citation: Biomarker Research 2023 11:99
  5. Concurrent chemoradiotherapy (cCRT) is the mainstay of treatment for patients diagnosed with locally advanced non-small cell lung cancer (NSCLC). One significant challenge in the effectiveness of this therapy ...

    Authors: Diego de Miguel-Perez, Francisco Gabriel Ortega, Rosario Guerrero Tejada, Antonio Martínez-Única, Christine B. Peterson, Alessandro Russo, Muthukumar Gunasekaran, Andres F. Cardona, Victor Amezcua, Jose Antonio Lorente, Jose Expósito Hernández, Christian Rolfo and Maria Jose Serrano
    Citation: Biomarker Research 2023 11:98
  6. Genomic testing is crucial for the management of ovarian cancer. DNA from biopsies at diagnostic laparoscopies or interval debulking surgery after neoadjuvant chemotherapy, has a high failure rate. At relapse,...

    Authors: Maria Kfoury, Reda El Hazzaz, Claire Sanson, Felix Blanc Durand, Judith Michels, Emeline Colomba Blameble, Roseline Tang, Audrey Le Formal, Elodie Lecerf, Sebastien Gouy, Amandine Maulard, Patricia Pautier, Etienne Rouleau and Alexandra Leary
    Citation: Biomarker Research 2023 11:93
  7. Recent advances in circulating cell-free DNA (cfDNA) analysis from biofluids have opened new avenues for liquid biopsy (LB). However, current cfDNA LB assays are limited by the availability of existing informa...

    Authors: Neeti Swarup, Jordan Cheng, Irene Choi, You Jeong Heo, Misagh Kordi, Mohammad Aziz, Akanksha Arora, Feng Li, David Chia, Fang Wei, David Elashoff, Liying Zhang, Sung Kim, Yong Kim and David T.W. Wong
    Citation: Biomarker Research 2023 11:90

    The Correction to this article has been published in Biomarker Research 2023 11:96

  8. Pancreatic cancer is one of the most challenging cancers due to its high mortality rates. Considering the late diagnosis and the limited survival benefit with current treatment options, it becomes imperative t...

    Authors: María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, Enrique Aranda and Antonio Rodríguez-Ariza
    Citation: Biomarker Research 2023 11:88
  9. Major histocompatibility complex class I related chain A (MICA) is an important and stress-induced ligand of the natural killer group 2 member D receptor (NKG2D) that is expressed in various tumour cells. Give...

    Authors: Jing Zhang, Qizhi Luo, Xin Li, Junshuang Guo, Quan Zhu, Xiaofang Lu, Leiyan Wei, Zhiqing Xiang, Manqing Peng, Chunlin Ou and Yizhou Zou
    Citation: Biomarker Research 2023 11:86
  10. Extracellular vesicles (EVs) have considerable potential as diagnostic, prognostic, and therapeutic agents, in large part because molecular patterns on the EV surface betray the cell of origin and may also be ...

    Authors: Md. Khirul Islam, Misba Khan, Kamlesh Gidwani, Kenneth W. Witwer, Urpo Lamminmäki and Janne Leivo
    Citation: Biomarker Research 2023 11:85
  11. Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine tumour whose diagnosis includes evaluating calcitonin serum levels, which can present fluctuations unrelated to MTC. Here, we investigated circulating...

    Authors: Anna Citarella, Zein Mersini Besharat, Sofia Trocchianesi, Tanja Milena Autilio, Antonella Verrienti, Giuseppina Catanzaro, Elena Splendiani, Zaira Spinello, Silvia Cantara, Patrizia Zavattari, Eleonora Loi, Cristina Romei, Raffaele Ciampi, Luciano Pezzullo, Maria Grazia Castagna, Antonio Angeloni…
    Citation: Biomarker Research 2023 11:82
  12. Colorectal cancer is a major cause of cancer-related deaths worldwide. A third of colorectal cancers reside in the rectum. Many patients with rectal cancer present in the locally-advanced stage which needs mul...

    Authors: Parmida Sadat Pezeshki and Reza Ghalehtaki
    Citation: Biomarker Research 2023 11:81
  13. Small cell lung cancer (SCLC) has an exceptionally poor prognosis; as most of the cases are initially diagnosed as extensive disease with hematogenous metastasis. Therefore, the early diagnosis of SCLC is very...

    Authors: Dong Ha Kim, Hyojeong Park, Yun Jung Choi, Kyungtaek Im, Chae Won Lee, Da-Som Kim, Chan-Gi Pack, Hyun-Yi Kim, Chang-Min Choi, Jae Cheol Lee, Wonjun Ji and Jin Kyung Rho
    Citation: Biomarker Research 2023 11:80
  14. Growing evidence supports that extracellular vesicles (EVs) in blood plasma and other body fluids may function as biomarkers for disease. We previously found that secretory autophagosomes (SAPs), a kind of EV,...

    Authors: Xue-cheng Dong, Xin-yi Xu, Yue-ru Huang, Xing-xing Zhu, Yi Yang, Wei Huang and Ling Liu
    Citation: Biomarker Research 2023 11:79
  15. S100A6 (also called calcyclin) is a Ca2+-binding protein that belongs to the S100 protein family. S100A6 has many functions related to the cytoskeleton, cell stress, proliferation, and differentiation. S100A6 als...

    Authors: Yidian Wang, Xuewen Kang, Xin Kang and Fengguang Yang
    Citation: Biomarker Research 2023 11:78
  16. Extracellular vesicles (EVs) have garnered significant interest in the field of biomedical science due to their potential applications in therapy and diagnosis. These vesicles participate in cell-to-cell commu...

    Authors: Islam M. Saadeldin, Seif Ehab and Jongki Cho
    Citation: Biomarker Research 2023 11:77
  17. For early screening and diagnosis of non-small cell lung cancer (NSCLC), a robust model based on plasma proteomics and metabolomics is required for accurate and accessible non-invasive detection. Here we aim t...

    Authors: Runhao Xu, Jiongran Wang, Qingqing Zhu, Chen Zou, Zehao Wei, Hao Wang, Zian Ding, Minjie Meng, Huimin Wei, Shijin Xia, Dongqing Wei, Li Deng and Shulin Zhang
    Citation: Biomarker Research 2023 11:71
  18. Biomarkers are detectable molecules that can reflect specific physiological states of cells, organs, and organisms and therefore be regarded as indicators for specific diseases. And the discovery of biomarkers...

    Authors: Yongshu Li, Winnie Wailing TAM, Yuanyuan Yu, Zhenjian Zhuo, Zhichao Xue, Chiman Tsang, Xiaoting Qiao, Xiaokang Wang, Weijing Wang, Yongyi Li, Yanyang Tu and Yunhua Gao
    Citation: Biomarker Research 2023 11:70
  19. Chronic lymphocytic leukemia (CLL) is one of the most frequent occurring types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. At present, the molecular mechanis...

    Authors: Wenjie Zhang, Jinlan Long, Peixia Tang, Kaili Chen, Guangyao Guo, Zezhong Yu, Jie Lin, Liping Liu, Rong Zhan and Zhenshu Xu
    Citation: Biomarker Research 2023 11:58
  20. Lung cancer remains the leading cause of cancer mortality worldwide. Early detection of lung cancer helps improve treatment and survival. Numerous aberrant DNA methylations have been reported in early-stage lu...

    Authors: Shuo Hu, Jinsheng Tao, Minhua Peng, Zhujia Ye, Zhiwei Chen, Haisheng Chen, Haifeng Yu, Bo Wang, Jian-Bing Fan and Bin Ni
    Citation: Biomarker Research 2023 11:45
  21. Multiple myeloma (MM) is an incurable hematological cancer with high spatial- and temporal-heterogeneity. Invasive single-point bone marrow sampling cannot capture the tumor heterogeneity and is difficult to r...

    Authors: Shuchan Li, Enfan Zhang and Zhen Cai
    Citation: Biomarker Research 2023 11:27

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system. During the submission process you will be asked whether you are submitting to a Collection, please select "Liquid biopsy, cfDNA, and ctDNA: new technologies and clinical applications" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.